+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia-Pacific Cancer Screening Market Outlook 2020-2030

  • PDF Icon

    Report

  • 331 Pages
  • February 2022
  • Region: Asia Pacific
  • Research Nester Pvt. Ltd
  • ID: 5559886

Asia Pacific Cancer Screening Market Analysis 2020-2030


The Asia Pacific cancer screening market is anticipated to grow with a CAGR of 13.37% during the forecast period, i.e., 2021-2030. Factors such as the growing medical industry in the region, along with the increasing health expenditure, and the growing advancements in the field of healthcare technologies, are anticipated to drive the market growth in the coming years. Additionally, factors such as the rising incidences of cancer and the growing developments in cancer screening technologies are also projected to contribute to the market growth during the forecast period. The Asia Pacific cancer screening market is estimated to garner a revenue of more than USD 142540 Million by the end of 2030, up from a revenue of about USD 40980 Million in the year 2020.

The Asia Pacific cancer screening market is segmented by numerous segments, which include segmentation by screening type, product, application, end-user, and by country. By screening type, the market is segmented into laboratory tests, genetic tests, imaging, biopsy, endoscopy, and others. By the end of 2030, the imaging segment is projected to garner the largest revenue of close to USD 52360 Million, up from a revenue of about USD 15040 Million in the year 2020.

On the basis of country, the Asia Pacific cancer screening market is segmented into Australia, Japan, Singapore, South Korea, India, China, Taiwan, Vietnam, Thailand, Philippines, and the Rest of Asia Pacific. The market in China, amongst the market in all the other regions, is anticipated to garner the largest revenue of near to USD 62860 Million by the end of 2030. Moreover, in the year 2020, the market in the nation generated a revenue of about USD 17370 Million.

Some of the prominent industry leaders in the Asia Pacific cancer screening market that are included in our report are Abbott, General Electric, Hologic, Inc., Siemens Healthcare Private Limited, QIAGEN, F. Hoffmann-La Roche Ltd., Illumina, Inc., Novacyt Group, Koninklijke Philips N.V., MiRXES Pte Ltd., and others.

Table of Contents

1. Market Definition
1.1. Definition
1.2. Market Segmentation
2. Assumptions and Acronyms
3. Research Methodology
3.1. Research Process
3.2. Primary Research
3.3. Secondary Research
4. Executive Summary - Asia Pacific Cancer Screening Market
5. Analysis of Market Dynamics
5.1. Market Drivers
5.2. Market Restraints
6. Key Market Opportunities7. Major Roadblocks for the Market Growth8. Regulatory Landscape9. Industry Risk Analysis10. Pricing Analysis of Cancer Screening Market11. Value Chain Analysis12. Analysis on the Major Cancer Screening Tools13. Industry Growth Outlook14. Impact of COVID-19 on the Asia Pacific Cancer Screening Market
15. Asia Pacific Cancer Screening Market 2020-2030
15.1. Market Overview
15.2. By Value (USD Million)
15.3. Market Segmentation
15.3.1. By Screening Type
15.3.1.1. Laboratory Tests, 2020-2030F (USD Million)
15.3.1.2. Genetic Tests, 2020-2030F (USD Million)
15.3.1.3. Imaging, 2020-2030F (USD Million)
15.3.1.4. Biopsy, 2020-2030F (USD Million)
15.3.1.5. Endoscopy, 2020-2030F (USD Million)
15.3.1.6. Others, 2020-2030F (USD Million)
15.3.2. By Product
15.3.2.1. Consumables, 2020-2030F (USD Million)
15.3.2.2. Instruments, 2020-2030F (USD Million)
15.3.3. By Application
15.3.3.1. Lung Cancer, 2020-2030F (USD Million)
15.3.3.2. Breast Cancer, 2020-2030F (USD Million)
15.3.3.3. Melanoma, 2020-2030F (USD Million)
15.3.3.4. Kidney Cancer, 2020-2030F (USD Million)
15.3.3.5. Colorectal Cancer, 2020-2030F (USD Million)
15.3.3.6. Gastric Cancer, 2020-2030F (USD Million)
15.3.3.7. Others, 2020-2030F (USD Million)
15.3.4. By End-User
15.3.4.1. Hospitals & Clinics, 2020-2030F (USD Million)
15.3.4.2. Laboratories, 2020-2030F (USD Million)
15.3.4.3. Others, 2020-2030F (USD Million)
15.3.5. By Country
15.3.5.1. Australia, 2020-2030F (USD Million)
15.3.5.2. Japan, 2020-2030F (USD Million)
15.3.5.3. Singapore, 2020-2030F (USD Million)
15.3.5.4. South Korea, 2020-2030F (USD Million)
15.3.5.5. India, 2020-2030F (USD Million)
15.3.5.6. China, 2020-2030F (USD Million)
15.3.5.7. Taiwan, 2020-2030F (USD Million)
15.3.5.8. Vietnam, 2020-2030F (USD Million)
15.3.5.9. Thailand, 2020-2030F (USD Million)
15.3.5.10. Philippines, 2020-2030F (USD Million)
15.3.5.11. Rest of Asia Pacific, 2020-2030F (USD Million)
16. Australia Cancer Screening Market 2020-2030
16.1. Market Overview
16.2. By Value (USD Million)
16.3. Market Segmentation
16.3.1. By Screening Type
16.3.1.1. Laboratory Tests, 2020-2030F (USD Million)
16.3.1.2. Genetic Tests, 2020-2030F (USD Million)
16.3.1.3. Imaging, 2020-2030F (USD Million)
16.3.1.4. Biopsy, 2020-2030F (USD Million)
16.3.1.5. Endoscopy, 2020-2030F (USD Million)
16.3.1.6. Others, 2020-2030F (USD Million)
16.3.2. By Product
16.3.2.1. Consumables, 2020-2030F (USD Million)
16.3.2.2. Instruments, 2020-2030F (USD Million)
16.3.3. By Application
16.3.3.1. Lung Cancer, 2020-2030F (USD Million)
16.3.3.2. Breast Cancer, 2020-2030F (USD Million)
16.3.3.3. Melanoma, 2020-2030F (USD Million)
16.3.3.4. Kidney Cancer, 2020-2030F (USD Million)
16.3.3.5. Colorectal Cancer, 2020-2030F (USD Million)
16.3.3.6. Gastric Cancer, 2020-2030F (USD Million)
16.3.3.7. Others, 2020-2030F (USD Million)
16.3.4. By End-User
16.3.4.1. Hospitals & Clinics, 2020-2030F (USD Million)
16.3.4.2. Laboratories, 2020-2030F (USD Million)
16.3.4.3. Others, 2020-2030F (USD Million)
17. Japan Cancer Screening Market 2020-2030
17.1. Market Overview
17.2. By Value (USD Million)
17.3. Market Segmentation
17.3.1. By Screening Type
17.3.2. By Product
17.3.3. By Application
17.3.4. By End-User
18. Singapore Cancer Screening Market 2020-2030
18.1. Market Overview
18.2. By Value (USD Million)
18.3. Market Segmentation
18.3.1. By Screening Type
18.3.2. By Product
18.3.3. By Application
18.3.4. By End-User
19. South Korea Cancer Screening Market 2020-2030
19.1. Market Overview
19.2. By Value (USD Million)
19.3. Market Segmentation
19.3.1. By Screening Type
19.3.2. By Product
19.3.3. By Application
19.3.4. By End-User
20. India Cancer Screening Market 2020-2030
20.1. Market Overview
20.2. By Value (USD Million)
20.3. Market Segmentation
20.3.1. By Screening Type
20.3.2. By Product
20.3.3. By Application
20.3.4. By End-User
21. China Cancer Screening Market 2020-2030
21.1. Market Overview
21.2. By Value (USD Million)
21.3. Market Segmentation
21.3.1. By Screening Type
21.3.2. By Product
21.3.3. By Application
21.3.4. By End-User
22. Taiwan Cancer Screening Market 2020-2030
22.1. Market Overview
22.2. By Value (USD Million)
22.3. Market Segmentation
22.3.1. By Screening Type
22.3.2. By Product
22.3.3. By Application
22.3.4. By End-User
23. Vietnam Cancer Screening Market 2020-2030
23.1. Market Overview
23.2. By Value (USD Million)
23.3. Market Segmentation
23.3.1. By Screening Type
23.3.2. By Product
23.3.3. By Application
23.3.4. By End-User
24. Thailand Cancer Screening Market 2020-2030
24.1. Market Overview
24.2. By Value (USD Million)
24.3. Market Segmentation
24.3.1. By Screening Type
24.3.2. By Product
24.3.3. By Application
24.3.4. By End-User
25. Philippines Cancer Screening Market 2020-2030
25.1. Market Overview
25.2. By Value (USD Million)
25.3. Market Segmentation
25.3.1. By Screening Type
25.3.2. By Product
25.3.3. By Application
25.3.4. By End-User
26. Rest of Asia Pacific Cancer Screening Market 2020-2030
26.1. Market Overview
26.2. By Value (USD Million)
26.3. Market Segmentation
26.3.1. By Screening Type
26.3.2. By Product
26.3.3. By Application
26.3.4. By End-User
27. Competitive Landscape
27.1. Company Market Share Analysis
27.2. Company Profiles
27.2.1. Abbott
27.2.2. General Electric
27.2.3. Hologic, Inc.
27.2.4. Siemens Healthcare Private Limited
27.2.5. QIAGEN
27.2.6. F. Hoffmann-La Roche Ltd.
27.2.7. Illumina, Inc.
27.2.8. Novacyt Group
27.2.9. Koninklijke Philips N.V.
27.2.10. MiRXES Pte Ltd.

Companies Mentioned

  • Abbott
  • General Electric
  • Hologic Inc.
  • Siemens Healthcare Private Limited
  • QIAGEN
  • F. Hoffmann-La Roche Ltd.
  • Illumina Inc.
  • Novacyt Group
  • Koninklijke Philips N.V.
  • MiRXES Pte Ltd.